Carbohydrate polymers · 2026
Structural validation and immunogenic characterization of Streptococcus pneumoniae serotype 22A capsular polysaccharide relative to serotype 22F.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Meng Xiongyan, Yang Huimin, Xue Yannan, Zhong Yingjie, Wang Siqi, Li Chen, Liu Xiao, Meng Shuai, Li Jianping, Sun Tiantian, Zong Chengli
Аннотация
Streptococcus pneumoniae serotype 22A is a significant contributor to invasive pneumococcal disease (IPD) in selected regions and is closely related to the vaccine-included serotype 22F. The repeating unit (RU) structure of serotype 22A capsular polysaccharide (CPS) was reported in a patent. In this study, we performed a comprehensive structural validation combining chemical derivatization, high-resolution MS, and NMR spectroscopy to confirm the RU structure, O-acetylation pattern, as well as its immunological characterization relative to 22F. The RU of 22A CPS was confirmed as: [→3)-β-D-Galf-(1 → 2)-α-L-Rhap-(1 → 4)-β-D-GlcAp-(1 → 4)-(α-D-Galp-(1 → 3))-β-L-Rhap-(2-OAc)(1 → 4)-β-D-Glcp-(1→]n. It is highly similar to that of 22F, with the key difference being a side chain α-d-galactopyranose in 22A versus α-d-glucopyranose in 22F. O-acetylation was also identified as an important structural feature. Immunogenicity was assessed using 22A and 22F CPS-CRM197 conjugates in rabbits. Both vaccines elicited robust antibody responses. Glycan microarray analysis revealed cross-reactive binding between 22A and 22F, while also demonstrating that O-acetyl group is a key contributing factor for antibody recognition. These findings provide the detailed structural characterization of 22A CPS, establish its distinction from 22F, and highlight the roles of side chain sugar and O-acetylation in immunogenicity, offering guidance for pneumococcal vaccine design.